Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors.
Recent studies have shown that proteoglycans play an important role in the development of vascular disease and renal failure. In this study, the effects of angiotensin II (AngII) type 1 (AT1) and type 2 (AT2) receptor stimulation on glycosaminoglycan and proteoglycan core protein synthesis in vascular smooth muscle cells (VSMC) were examined. Treatment of AT1 receptor-expressing VSMC with AngII resulted in a dose-dependent and time-dependent increase (2- to 4-fold) in (3)H-glucosamine/(35)S-sulfate incorporation, which was abolished by pretreatment with the AT1 receptor antagonist, losartan. The effects of AngII were inhibited by the epidermal growth factor receptor inhibitor, AG1478, and the mitagen-activated protein kinase kinase inhibitor, PD98059, but not the protein kinase C inhibitors, chelerythrine and staurosporine. AngII treatment also resulted in significant increases in the mRNA of the core proteins, versican, biglycan, and perlecan. The effects of AT2 receptor stimulation were examined by retroviral transfection of VSMC with the AT2 receptor. Stimulation of the AT2 receptor in these VSMC-AT2 cells resulted in a significant (1.3-fold) increase in proteoglycan synthesis, which was abolished by the AT2 receptor antagonist, PD123319, and attenuated by pretreatment with pertussis toxin. These results implicate both AT1 and AT2 receptors in the regulation of proteoglycan synthesis and suggest the involvement of epidermal growth factor receptor-dependent tyrosine kinase pathways and G alpha i/o-mediated mechanisms in the effects of the two receptors.
Shimizu-Hirota
Ryoko
R
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Sasamura
Hiroyuki
H
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Mifune
Mizuo
M
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Nakaya
Hideaki
H
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Kuroda
Mari
M
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Hayashi
Matsuhiko
M
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Saruta
Takao
T
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
D053674:Aggrecans; D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D002478:Cells, Cultured; D018076:DNA, Complementary / Q000235:genetics; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins / Q000235:genetics; D019812:Heparan Sulfate Proteoglycans / Q000235:genetics; D007093:Imidazoles / Q000494:pharmacology; D037181:Lectins, C-Type; D019808:Losartan / Q000494:pharmacology; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011509:Proteoglycans / Q000096:biosynthesis*; D011725:Pyridines / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000502:physiology*
C508321:Acan protein, rat; D053674:Aggrecans; D057911:Angiotensin Receptor Antagonists; D018076:DNA, Complementary; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D019812:Heparan Sulfate Proteoglycans; D007093:Imidazoles; D037181:Lectins, C-Type; D011509:Proteoglycans; D011725:Pyridines; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C073402:PD 123319; C071927:perlecan; D019808:Losartan